Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525291 | 1.00 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL30037767 | 1.00 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL20465744 | 0.82 | ERN1 (0.52) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL19429 | 0.82 | ERN1 (0.52) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL21676110 | 0.79 | SMN1; SMN2 (0.42) | ERN1CYP2A6PTGDR2ALDH1A1DGAT1 | |
| SCHEMBL3040456 | 0.78 | ERN1 (0.64) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL16960006 | 0.77 | ERN1 (0.42) | ERN1PTGDR2ALDH1A1DGAT1SMN1; SMN2 | |
| SCHEMBL2286127 | 0.77 | ERN1 (0.38) | ERN1ALDH1A1DGAT1SMN1; SMN2GPR183 | |
| SCHEMBL27701174 | 0.77 | ERN1 (0.38) | ERN1ALDH1A1DGAT1SMN1; SMN2GPR183 | |
| SCHEMBL65723 | 0.76 | ERN1 (0.56) | ERN1PTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119116-A | Rhein phosphoryl derivative and synthetic method and application thereof | 甘肃中医药大学 | 2024-12-13 | — | — | CN | claimed |
| CN-113912544-B | Preparation method of 5-bromo-1-methylindazole | 沧州普瑞东方科技有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-113912544-A | Preparation method of 5-bromo-1-methylindazole | 沧州普瑞东方科技有限公司 | 2022-01-11 | — | — | CN | claimed |
| CN-108623558-A | A kind of synthetic method of 2- (the bromo- 2- luorobenzyls of 5-) benzothiophene | 瑞孚信江苏药业股份有限公司 | 2018-10-09 | — | — | CN | claimed |
| CN-105924403-B | A kind of ring propane diamide compound with anti-tumor activity and its preparation method and application | 西安交通大学 | 2018-07-17 | — | — | CN | claimed |
| CN-105924385-A | Diarylthiourea compound with antitumor activity, and preparation method and application thereof | 西安交通大学 | 2016-09-07 | — | — | CN | claimed |
| CN-105924403-A | Cyclomalonamide compound with antitumor activity, and preparation method and application thereof | 西安交通大学 | 2016-09-07 | — | — | CN | claimed |
| CN-104744358-A | Pyridine formylhydrazine compounds with insecticidal activity and preparation method and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2015-07-01 | — | — | CN | claimed |
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | claimed |
| JP-2007500725-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010910-A | Biazacycloalkane Menin-MLL protein inhibitor, pharmaceutical composition and application thereof | 赛诺哈勃药业（成都）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-5731315-A | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-03-24 | — | — | US | disclosed |
| US-5489592-A | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETES-RELATED DISORDERS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1996-02-06 | — | — | US | disclosed |
| EP-0607344-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007109-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | OGDH, ME1, GCDH | ERN1 3645/4885CYP2A6 639/4885PTGDR2 1578/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | ERN1 1001/4885CYP2A6 404/4885PTGDR2 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.